Understanding IBA's Share Buyback Program
In a move aimed at reinforcing its commitment to shareholders, IBA (Ion Beam Applications S.A.) has launched a significant share buyback program. This initiative is part of the company’s ongoing strategy to manage its equity efficiently and align its financial resources with long-term company objectives. The buyback program was officially announced on March 24, 2025, and is in accordance with Belgian regulations governing corporate share repurchases.
Details of the Buyback Program
Under this program, IBA is authorized to repurchase up to 650,000 ordinary shares. This effort is not merely a financial maneuver but is closely aligned with the company’s long-term incentive plans for management and key personnel. These plans are designed to motivate and retain top talent, ensuring IBA remains at the forefront of innovation in the industry.
Execution Period and Initial Transactions
The share repurchases began on March 25, 2025, and are scheduled to continue until December 31, 2025. So far, from April 1 to April 7, 2025, IBA successfully repurchased a total of 43,000 shares. These transactions were executed on Euronext Brussels, where the company is listed, reflecting transparency and accountability in the process.
Breakdown of Recent Share Purchases
During the initial days of the buyback program, the following trades took place:
- April 1, 2025: 6,000 shares at an average price of 11.05 €.
- April 2, 2025: 8,000 shares at an average price of 10.83 €.
- April 3, 2025: 9,000 shares at an average price of 10.57 €.
- April 4, 2025: 10,000 shares at an average price of 10.17 €.
- April 7, 2025: 10,000 shares at an average price of 10.08 €.
The total amount spent on these purchases reaches approximately 450,675.30 €, showcasing the company’s financial strength and commitment to its strategic goals.
Current Treasury Shares Situation
As of now, IBA holds a total of 136,017 shares repurchased under this buyback initiative. When examining IBA’s treasury shares, the company directly holds 449,596 shares, in addition to 51,973 shares held through its subsidiary, IBA Investments SRL. The cumulative total of treasury shares stands at 501,569, representing about 1.66% of the total issued shares.
Broader Implications for IBA
This buyback program reflects IBA’s ongoing commitment to enhancing shareholder value while strategically managing its capital. As a leader in particle accelerator technology, IBA is focused on expanding its market share in proton therapy and other advanced medical technologies. The firm’s ethical approach to business is also noteworthy; as a certified B Corporation, it adheres to reputable standards of social and environmental performance.
About IBA
IBA has established itself as the leading provider of equipment and services in the realm of proton therapy, capitalizing on its global expertise of over 2,100 employees. The firm’s innovative solutions are vital for patients globally, significantly improving treatment outcomes in radiation therapy. By being listed on the pan-European stock exchange EURONEXT, IBA continues to attract attention from investors interested in impactful technology.
For further inquiries, investors and interested parties can reach out to:
IBA
Thomas Pevenage,
Investor Relations
investorrelations@iba-group.com
Frequently Asked Questions
What is the purpose of IBA's share buyback program?
The program aims to manage equity efficiently and align financial resources with long-term objectives, including retaining top talent.
How many shares is IBA authorized to repurchase?
IBA is authorized to repurchase up to 650,000 ordinary shares as part of this initiative.
What has been the total spent on recent share repurchases?
Approximately 450,675.30 € has been spent on the purchase of the initially repurchased shares.
How does IBA demonstrate its commitment to sustainable practices?
As a certified B Corporation, IBA meets high standards of social and environmental performance, emphasizing ethical business practices.
In which sectors does IBA operate?
IBA specializes in particle accelerator technology, focusing on proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry.
